Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADCY5 | O95622 | 5/20 | 0.48 |
| ▸ | P2RY1 | P47900 | 6/20 | 0.45 |
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.45 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.44 |
| ▸ | AHCY | P23526 | 1/20 | 0.42 |
| ▸ | ENPP1 | P22413 | 1/20 | 0.42 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19503356 | 1.00 | ADCY5 (0.48) | ADCY5P2RY1ADORA3ADORA2AAHCY | |
| SCHEMBL10475246 | 0.84 | AHCY (0.58) | ADCY5ADORA3ADORA2AAHCY | |
| SCHEMBL19503483 | 0.82 | PDE4D (0.57) | ADCY5ADORA3ADORA2A | |
| SCHEMBL19503306 | 0.82 | PDE4D (0.57) | ADCY5ADORA3ADORA2A | |
| SCHEMBL29319046 | 0.81 | P2RY1 (0.42) | P2RY1ADORA2AENPP1P2RY12 | |
| SCHEMBL19503474 | 0.81 | AHCY (0.49) | P2RY1ADORA3AHCYENPP1P2RY12 | |
| SCHEMBL11363312 | 0.79 | ADORA2A (0.58) | P2RY1ADORA3ADORA2AENPP1P2RY12 | |
| SCHEMBL10474172 | 0.78 | ADCY5 (0.74) | ADCY5ADORA3ADORA2AAHCY | |
| SCHEMBL12330956 | 0.77 | AHCY (0.56) | P2RY1AHCYENPP1P2RY12 | |
| SCHEMBL16290177 | 0.77 | AHCY (0.56) | P2RY1AHCYENPP1P2RY12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3445368-B1 | COMPOUNDS AND METHODS FOR TREATING NEUROLOGICAL AND CARDIOVASCULAR CONDITIONS | ASTROCYTE PHARMACEUTICALS INC (US) | 2024-07-17 | — | — | EP | disclosed |